Galapagos reports additional data with filgotinib from the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study
  • Filgotinib: an investigational JAK-inhibitor shows efficacy in Crohn's disease
  • Clinical responses continued from week 10 to week 20
  • Safety profile similar to that previously observed
  • Phase 3 program in Crohn's disease to be initiated in 2016

Mechelen, Belgium, April 21, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn's disease. 

174 patients with moderately to severely active Crohn's disease were enrolled in FITZROY, a double-blind, placebo-controlled Phase 2 study.  Patients recruited were either anti-TNF naïve or anti-TNF failures.  The study comprised two parts each of 10 weeks duration: the first part - reported in December 2015 - investigated the safety and efficacy of filgotinib 200 mg once daily versus placebo.  The FITZROY study achieved the primary endpoint of clinical remission at 10 weeks: the percentage of patients achieving a Crohn's Disease Activity Index (CDAI) score lower than 150 was significantly higher in patients treated with filgotinib versus patients receiving placebo.  Improvement in histopathology and endoscopy assessments were observed at Week 10.  Further evaluation is ongoing.

The second part of the study investigated continued treatment through 20 weeks in an exploratory analysis that was not powered for statistical significance.  Clinical responses continued from week 10 to week 20.  Non-responders in the placebo arm from the first ten weeks received filgotinib 100 mg in the second ten weeks and showed improvement in clinical remission during the second part of the study.

There were no new safety signals during the second part of the FITZROY study, consistent with the profile of filgotinib previously described.  Most common adverse events observed during this study were infections, gastrointestinal disorders and nervous system disorders.  There were no gastrointestinal perforations, no cancers and no deaths reported during the study.

Galapagos and Gilead Sciences intend to submit the FITZROY 20-week results to future medical conferences.

"We are pleased by the outcome of the FITZROY study, positioning filgotinib as a potential oral treatment for patients with Crohn's disease.  The observed safety profile of filgotinib further strengthens its promising efficacy," said Piet Wigerinck, Chief Scientific Officer at Galapagos.  "We are proud to be advancing what could become the first new oral treatment for Crohn's disease in decades."

Galapagos and Gilead entered into a global partnership for the development and commercialization of filgotinib for inflammatory indications.  Gilead intends to initiate a Phase 3 study with filgotinib in Crohn's disease later in 2016.  

About Crohn's disease Crohn's disease (CD) is an inflammatory bowel disease causing chronic inflammation of the gastrointestinal, or GI, tract with a relapsing and remitting course.  The prevalence estimates for CD in North America range from 44 cases to 201 cases per 100,000 persons and in Europe, from 37.5 cases to 238 cases per 100,000 persons.  The disease is slightly more common in women, with a peak incidence at the age of 20 to 40 years.  The disease is characterized by inflammation that may affect any part of the GI tract from mouth to anus, but most commonly the distal small intestine and proximal colon, causing a wide variety of symptoms including anemia, abdominal pain, diarrhea, vomiting, and weight loss.  The characteristic inflammatory response of CD is focal transmural inflammation, frequently associated with granuloma formation, which may evolve to progressive damage over time.  Treatment of CD will depend on severity of the disease.  The main goal of treatment is to reduce inflammation in the intestine, prevent flares and keep patients' disease in remission.  While mild symptoms may respond to an antidiarrheal medicine, antibiotics, and other medicines to control inflammation, severe symptoms are often treated with anti-TNF agents.  Anti-TNF agents, however, do not work for all patients, and, in patients who do find therapeutic benefit, they can lose their effect over time as a result of relapse.  

About filgotinib Filgotinib is an investigational, selective JAK1 inhibitor discovered and developed by Galapagos using its target and drug discovery technology platform.  In addition to the promising efficacy and safety with filgotinib in Crohn's disease, filgotinib has also been studied in rheumatoid arthritis (RA) with over 700 patient years of experience.  Galapagos and Gilead have a global partnership for the development and commercialization of filgotinib for inflammatory indications.  Gilead is preparing to initiate a Phase 3 program with filgotinib in RA and Crohn's disease in 2016. 

About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Our pipeline comprises a maturing pipeline of Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.  We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world.  Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives.  The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  More information at www.glpg.com .

Contacts

Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corp Communications +1 781 460 1784 Director Communications +31 6 53 591 999
  Paul van der Horst Director IR & Business Development +31 6 53 725 199 communications@glpg.com    
ir@glpg.com  

Galapagos Forward-Looking Statements This release may contain forward-looking statements, including statements regarding any guidance given by Galapagos' management, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies.  Galapagos cautions the reader that forward-looking statements are not guarantees of future performance.  Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.  In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  Among the factors that may result in differences are that Galapagos' expectations regarding its  the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos' product candidates.  A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

GLGP reports additional data from Phase 2 FITZROY study http://hugin.info/133350/R/2005809/741005.pdf

HUG#2005809

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 103

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 0

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 188

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 190

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 27

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 8

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Disclosure on Rathbones Group and De La Rue Plc

Updated Category News Views 144

Key Public Position Disclosure for Rathbones Group Plc Understanding the dynamics behind stock holding and market behavior is crucial for investors and stakeholders. This article sheds light on the recent public opening position disclosure made by Rathbones Group Plc regarding its interests in De La Rue Plc. According to the regulations of the Takeover Code, disclosers...

Continue Reading
ThinkAndor® Reigns as Leading AI Platform for Virtual Care

Updated Category News Views 132

ThinkAndor® Wins Top Honors in Virtual Care Solutions Andor Health's ThinkAndor® has distinguished itself yet again as the leading **AI healthcare software infrastructure**, confirmed by recent evaluations as the best virtual care platform. This notable recognition by an acclaimed market research assessment underscores the platform's unmatched capabilities in bringing...

Continue Reading
Jayud Global Logistics: Legal Actions and Investment Alerts

Updated Category News Views 165

Understanding the Securities Fraud Class Action Against Jayud The Law Offices of Howard G. Smith have announced a significant legal development involving Jayud Global Logistics Limited (NASDAQ: JYD). A class action lawsuit has been initiated on behalf of investors who purchased Jayud securities. The lawsuit covers shares bought during a specific period, and affected...

Continue Reading
Exploring the Explosive Growth of the 3D Printing Market

Updated Category News Views 101

3D Printing Market Size Analysis As of 2023, the 3D printing market was valued at USD 21.1 billion and is expected to grow to USD 118.9 billion by 2032, reflecting a compound annual growth rate (CAGR) of 21.2% during the forecast period. Current Trends Fueling Growth The 3D printing industry is experiencing remarkable expansion, driven by technological innovations and...

Continue Reading
Nexus Industrial REIT Sells Legacy Properties and Expands Operations

Updated Category News Views 111

Nexus Industrial REIT Emphasizes Focus on Industrial Real Estate Nexus Industrial REIT is creating a buzz in the market with its recent strategic initiatives. The company has officially offloaded a 50% stake in six office buildings, reinforcing its concentration on industrial properties. This transaction signifies a key moment, bolstering Nexus's standing as a prominent...

Continue Reading